8-(1H-indol-4-yl)-2-morpholin-4-yl-6-(1S,4S)-2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl-9H-purine | 1392421-78-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 8-(1H-indol-4-yl)-2-morpholin-4-yl-6-(1S,4S)-2-oxa-5-aza-bicyclo[2.2.1]hept-5-yl-9H-purine
• 英文别名: (1S,4S)-5-[8-(1H-indol-4-yl)-2-morpholin-4-yl-7H-purin-6-yl]-2-oxa-5-azabicyclo[2.2.1]heptane
• CAS: 1392421-78-1
• 化学式: C₂₂H₂₃N₇O₂
• 分子量: 417.47
• InChiKey: RTASTCNILVYNIH-KBPBESRZSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  95.2
• 氢给体数：
  2
• 氢受体数：
  7

文献信息

• [EN] NOVEL HETEROCYCLIC DERIVATIVES<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES INÉDITS
  申请人：NOVARTIS AG

  公开号：WO2012104776A1

  公开（公告）日：2012-08-09

  The invention relates to novel heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification, to their preparation, to their medical use, in particular to their use in the treatment of cancer and neurodegenrative disorders, and to medicaments comprising them.

  本发明涉及公式（I）的新型杂环化合物，其中所有变量均如规范中所定义，涉及其制备、医学用途，特别是涉及其在癌症和神经退行性疾病治疗中的应用，以及包含它们的药物。
• Novel Heterocyclic Derivatives
  申请人：RADETICH Branko

  公开号：US20120220576A1

  公开（公告）日：2012-08-30

  The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, to their preparation, to their medical use, in particular to their use in the treatment of cancer and neurodegenerative disorders, and to medicaments comprising them.

  本发明涉及新型杂环化合物，其化学式为上述式子，其中所有变量均如规范中定义的那样，以及它们的制备方法，它们在医学上的用途，特别是它们在癌症和神经退行性疾病治疗中的用途，以及包含它们的药物。
• NOVEL HETEROCYCLIC DERIVATIVES
  申请人：RADETICH Branko

  公开号：US20150344479A1

  公开（公告）日：2015-12-03

  The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, to their preparation, to their medical use, in particular to their use in the treatment of cancer and neurodegenerative disorders, and to medicaments comprising them.

  本发明涉及一种新型杂环化合物，其化学式为，在该式中所有变量的定义均如规范中所述，以及它们的制备方法、医药用途，特别是它们在癌症和神经退行性疾病治疗中的应用，以及包含它们的药物。
• US8987257B2
  申请人：——

  公开号：US8987257B2

  公开（公告）日：2015-03-24
• US9458163B2
  申请人：——

  公开号：US9458163B2

  公开（公告）日：2016-10-04